GRAL GRAIL, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:42
Jun 26
Jun 26
The author notes that GRAL is a spin-off from ILMN.
The author notes that GRAL is a spin-off from ILMN, providing factual context without expressing a directional view on either ticker.
LOW
19:33
Jun 04
Jun 04
The author asks a brief question about GRAL in response to news on lung cancer detection.
The author asks a brief question about GRAL in response to news on lung cancer detection proteins, without stating a position.
LOW
02:00
May 28
May 28
The tweet notes a clean breakout in GRAL in hindsight.
The tweet notes a clean breakout in GRAL in hindsight, but lacks a forward-looking opinion or trade call, making it a factual observation.
LOW
20:08
May 06
May 06
Reports good earnings for GRAL and observes price breakout from consolidation.
Reports good earnings for GRAL and observes price breakout from consolidation, no directional commitment.
LOW
09:42
May 05
May 05
Grail test FDA-rejected, high false positive rate
Short Grail — its flagship cancer screening test lacks FDA approval due to an unacceptably high false positive rate, meaning the core product is clinically unreliable and commercially impaired; the business case rests on a test that is "more wrong than right."
MED
08:30
Feb 10
Feb 10
Quest provides phlebotomy logistics for Grail's multi-cancer early detection test, representing a modest but growing revenue stream and validating Grail's clinical deployment.
HIGH
19:15
Feb 09
Feb 09
Buy GRAL on multiple converging catalysts — HIMS partnership, FDA approval progress.
Buy GRAL on multiple converging catalysts — HIMS partnership, FDA approval progress, and supportive legislation — with speaker viewing $100 as new support after missing a lower re-entry, implying continued upside from current levels.
MED
About GRAL Analyst Coverage
Buzzberg tracks GRAL (GRAIL, Inc. Common Stock) across 3 sources. 1 bullish vs 1 bearish calls from 3 analysts. Sentiment: evenly split. 7 total trade ideas tracked. Latest voices: incomesharks, CryptoCondom, Jim Davis.